Navigation Links
Cytel Hires Biopharmaceutical Development Veteran Jim Baker to Support Expansion of its Clinical Research Offerings
Date:3/18/2011

CAMBRIDGE, Mass., March 18, 2011 /PRNewswire/ -- Cytel Inc., premier provider of clinical trial design and implementation services and software, proudly announced today the addition of pharmaceutical and biotech industry veteran Jim Baker as Vice President, Clinical Research Services.

Over his 28 year career, Baker has demonstrated biopharmaceutical development leadership at some of the world's top pharmaceutical, biotech and clinical research firms including Amgen®, Wyeth® and Parexel®. Most recently Baker served as Senior Director of Study Standards Implementation at Millennium®.

Jim Baker is respected not only for his cross-functional experience spanning both development planning and clinical operations, but also equally for his in-depth trial data management knowledge.

Cytel CEO Ranganath Nayak remarked: "Jim's talent and track record are a precise match for Cytel's expanding line of innovative Clinical Research Services. Our customers will be happy that we have someone who has walked many a mile in their shoes and understands not only what their needs are but also how best to align Cytel's capabilities with those needs."

Baker has officially assumed his new position and it is our distinct pleasure to welcome him as the newest member of the Cytel management team.

About Cytel

Cytel Inc. is a leading provider of clinical research services and trial design and analysis software primarily for the biopharmaceutical and medical device development markets.

Cytel pioneered the statistical science of adaptive clinical trials and has designed more validated adaptive trials than any other service provider. Cytel software is used by 47 of the top 50 biopharmaceutical companies to d
'/>"/>

SOURCE Cytel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies
2. Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
3. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
4. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
5. Accuray Hires Chief Marketing Officer
6. PharMEDium Hires Thomas W. Rasnic as Vice President, Quality, Regulatory Affairs and Research and Development
7. Pharmaceutical Institute Hires Nathan Pienkowski, Ph.D., to Head Instructional Design
8. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
9. Accuray Hires General Manager for the Asia Pacific Region
10. Diplomat Specialty Pharmacy Launches Diplomat University - Hires Jennifer Hagerman, PharmD, Pharmacy Professor
11. Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014  Perrigo Company plc (NYSE: ... laws of Ireland (the " Company ... (the "Exchange Offer") up to $500,000,000 of its new 1.30% ... $600,000,000 of its new 2.30% Senior Notes due 2018 (the ... Senior Notes due 2023 (the " 2023 Exchange Notes ") ...
(Date:10/2/2014)...   Softworld, Inc. announced today the launch of ... on the specific needs of pharmaceutical, biotech, and medical ... been highly successful in the clinical domain, the team ... the quality, regulatory, and validation space. ... the current Biometric team and the newly created Life ...
(Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, ... following webcast:What: , Webcast and conference call to ... 2 clinical studies of ISIS-SMN Rx in ... which will be presented on the morning (CEST) ... World Muscle Society in Berlin, GermanyWhen:Friday, October 10 ...
Breaking Medicine Technology:Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2
... - Data From Phase 3 Study Presented at ... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... clinical trial that show patients with relapsed,and/or refractory ... treated with the mTOR (mammalian target of rapamycin) ...
... Show 100-Fold More Radiation Delivered to Tumor as Compared ... to Other Organs-, -All Patients ... ... TUSTIN, Calif., May 31 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported that ...
Cached Medicine Technology:New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 2New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 3New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 4New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 5New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 6Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 2Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 3Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 4Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 5
(Date:10/2/2014)... (PRWEB) October 02, 2014 Recently, BambooIndustry.com, ... unveiled its new collection of bamboo floors . ... for a lot of its products at the moment. ... is up to 26 percent off. The promotion will ... bamboo floors ( http://www.bambooindustry.com ) are all made by ...
(Date:10/2/2014)... 02, 2014 Originally considered alternative ... is becoming increasingly popular with consumers. This has ... Poultry Farming industry in Australia. According to ... organic meat has surged over the past five ... the farming level.” Over the five years through ...
(Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... of developing celiac disease isn,t reduced by breast-feeding. Nor will ... gluten to an infant,s diet help prevent celiac disease. ... studies in the Oct. 2 New England Journal of ... that a child could avoid celiac disease if mothers breast-feed ...
(Date:10/2/2014)... by scientists at The University of Nottingham could lead ... painkiller. , A drug resulting from the research, published ... offer new hope to sufferers of chronic pain conditions ... painkillers are currently available. , The work, led by ... Sciences, in collaboration with David Bates, Professor of Oncology ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Medical discovery first step on path to new painkillers 2
... high-dose technology targets tumor tissue, experts say , MONDAY, ... doesn,t harm the sexual function of prostate cancer patients, ... Cancer Center in Philadelphia tracked 155 men with intermediate- ... (IMRT), a technique that more precisely targets the tumor. ...
... The implementation of the Physical Agents Directive 2004/40/EC ... diagnosis and treatment Europe wide. Last Fridays publicly ... brakes on a feared future for Magnetic Resonance ... dialogue prior to policy is paramount , ...
... emerging threats to global health and ... diseases, NEW YORK, Oct. 29 The ... achievements in public health. However, the,increased incidence and ... and the re-emergence of tuberculosis, present critical,health challenges ...
... major study published in the November,2007 edition of the ... who completed a study using the Brava System increased,their ... breast size. This key,finding was based on a medical ... M.D. and Alexandra Kaider, M. Sc. The study is ...
... reminder program, TORONTO, Oct. 29 /PRNewswire/ - ... Today! reminder program for its Linessa(R) and,Nuvaring(R) contraceptive ... that helps them remember their contraceptives and,Organon Canada ... and patients. Organon Canada initiated the Remind ...
... of the Achilles tendon can experience a reduction in ... dextrose solution, according to a recent study conducted by ... Chronic tendinosis is a common overuse injury which can ... tendons throughout the body, said Norman J. Maxwell, MD, ...
Cached Medicine News:Health News:Prostate Cancer Radiotherapy Won't Affect Sexual Function 2Health News:Controversial physical agents directive postponed 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 3Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 4Health News:Newly Published Study in Leading Medical Journal Further Confirms the Brava System's Non-Surgical Breast Enhancement Effectiveness 2Health News:Telecommunications Technology Boosts Revenue Generation by Billions and Builds Positive Brand Experience 2Health News:Telecommunications Technology Boosts Revenue Generation by Billions and Builds Positive Brand Experience 3Health News:Ultrasound-guided injections help ease chronic Achilles tendon pain 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: